News >

Ponatinib Shows Promise in Pediatric/Adolescent ALL Patients

Jason Harris
Published: Tuesday, May 22, 2018

Stephanie E. Gruner, RN
Stephanie E. Gruner, RN
Ponatinib (Iclusig) induced a complete remission (CR) in one pediatric/adolescent patient with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), and demonstrated promising clinical activity in another, according to results from a case study presented at the 2018 American Society of Pediatric Hematology/Oncology (ASPHO) Conference.1

“It’s important to make it [clear] to clinicians that, when you do have a relapse or you’re seeing the BCR-ABL PCR is rising, consider mutational testing to identify these mutations and whether it’s clinically relevant to continue these drugs,” she said.

References

  1. Gruner SE, Sayeed H, Suarez-Ferguson L, et al. Ponatinib use in pediatric/adolescent and young adult patients with relapsed Ph+ ALL: a case series and review of the literature. Presented at: the 2018 ASPHO Conference; May 2-5, 2018; Pittsburgh, PA. Poster 079.
  2. Iclusic [package insert]. Cambridge, MA: ARIAD Pharmaceuticals Inc; 2017.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x